论文部分内容阅读
目的:探讨长链非编码RNA(long non-coding RNA,lnc RNA)肺癌转移相关转录本1(metastasis-associated lung adenocarcinoma transcript 1,MALAT1)在弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)患者血清中的表达水平及其与临床预后的相关性。方法:采集2010年1月至2015年12月期间在四川省人民医院血液科确诊的、临床资料完整的82例DLBCL患者和32例淋巴结反应性增生(reactive lymphoid hyperplasia,RLH)患者的血液标本,用实时荧光定量PCR法检测两组患者血清中lnc RNA MALAT1的表达水平,分析lnc RNA MALAT1表达水平与DLBCL患者临床病理特征及预后的关系。结果:DLBCL患者血清中lnc RNA MALAT1表达水平明显高于RLH患者(7.48±0.27 vs 1.28±0.45,P<0.01)。lnc RNA MALAT1的表达水平与肿瘤大小、临床分期、B症状及国际预后指数(international prognostic index,IPI)相关(均P<0.01)。高表达lnc RNA MALAT1的患者中位无进展生存时间明显短于低表达者[(16.43±2.05)vs(32.01±3.20)个月,P<0.01],lnc RNA MALAT1表达水平与IPI指数是影响DLBCL患者预后的独立因素(P<0.01)。结论:lnc RNA MALAT1在DLBCL患者中的高表达与多项临床病理参数有关,有望成为判断DLBCL患者预后的标志物。
OBJECTIVE: To investigate the role of long non-coding RNA (lnc RNA) metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) in diffuse large B-cell lymphoma , DLBCL) in patients with serum and its correlation with clinical prognosis. Methods: The blood samples from 82 patients with DLBCL and 32 patients with reactive lymphoid hyperplasia (RLH) who were diagnosed as hematology in Sichuan Provincial People ’s Hospital from January 2010 to December 2015 were collected. The expression of lnc RNA MALAT1 in serum was detected by real-time fluorescence quantitative PCR, and the relationship between lncRNA MALAT1 expression and clinicopathological features and prognosis of DLBCL patients was analyzed. Results: The expression of lnc RNA MALAT1 in patients with DLBCL was significantly higher than that in patients with RLH (7.48 ± 0.27 vs 1.28 ± 0.45, P <0.01). The expression level of lnc RNA MALAT1 was correlated with tumor size, clinical stage, B symptoms and international prognostic index (all P <0.01). The median progression-free survival time of lnc RNA MALAT1 patients was significantly shorter than that of low-expression ones [(16.43 ± 2.05) vs (32.01 ± 3.20) months, P <0.01]. The expression of lnc RNA MALAT1 and IPI index Independent prognostic factors (P <0.01). Conclusion: The overexpression of lnc RNA MALAT1 in DLBCL patients is associated with a number of clinicopathological parameters, which is expected to become a marker of prognosis in DLBCL patients.